Thrivent Financial for Lutherans
PRAX icon

Thrivent Financial for Lutherans’s Praxis Precision Medicines PRAX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,815
Closed -$66K – 2492
2022
Q4 		$66K Buy
+1,815
New +$56.6K ﹤0.01% 2393

Other funds holding PRAX

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TLP
Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Thrivent Financial for Lutherans's PRAX Position: Q1 2023 in Review

Thrivent Financial for Lutherans sold out of Praxis Precision Medicines (PRAX) in Q1 2023, closing a stake of 1,815 shares — an estimated $66K sold.

Thrivent Financial for Lutherans first reported a position in PRAX in Q4 2022 and held it in 1 quarter. The position peaked at $66K in Q4 2022. 86 funds tracked by Wall St. Rank hold PRAX as of Q1 2023.

  • Thrivent Financial for Lutherans reported no remaining Praxis Precision Medicines position as of Q1 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 1,815 Praxis Precision Medicines shares in Q1 2023, an estimated $66K.
  • Thrivent Financial for Lutherans first reported a position in Praxis Precision Medicines in Q4 2022 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Praxis Precision Medicines position peaked at $66K in Q4 2022.
  • 86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2023, filed 17 May 2023.